Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HL for pm play(?) earnings next week too..
or MELI?? earnings tonight in addition to sector-relation
also have MSTR BKNG MELI puts for earnings this week
thanks Ed! big question is can she dump 30% tomorrow ;)
ABNB picking up some steam to the downside ahead of earnings...
ABNB puts(?)
Thank you sir; appreciate it!
And what might these ‘civil’ penalties mean regarding D&O’s…
Wonder if this is purely paid to bond holders or spread across all the bk claimants? Paid soon at when bk closes? And we still don’t know the amount of the sec’s claim (?)
Sure hope so!
Thanks for posting
qcom 130p
see the huge sell in fb at 1pm?
level 2 looking like 'maybe' 140's possible?? we'll see EDIT tons of 160 bids just appeared
oich, what is the date or docket number for this as i'm having trouble finding it? thanks!
yep; not good at all and on their call now and not hearing much of anything except wait till end of year for more data(?)
'and' they need to raise funds 'somehow'
and there you have it...........
1) HUGE results that are going to make us billionaires OR 2) they really really need to raise money
please be 1...............
have to be a registered member to access recordings and slides:
https://coaconference.com/speakers/#keynote
from linkedin, would love to find the details of this presentation to see if anything at all to do with our tech
"
Community Oncology Alliance
6,458 followers
2w • 2 weeks ago
Follow
There have been some great new developments in drug treatment for non-small cell lung cancer. Melissa Johnson, MD, of the Sarah Cannon Research Institute taught attendees about these drugs today at #COA2022. Thank you Dr. Johnson!
1 comment
Current selected sort order is Most relevant
Most relevant
See profile for Ravi Bhardwaj Annamraju
Ravi Bhardwaj Annamraju
out of network3rd+
Digital Oncology | Radiology | AI & NLP | Product Mgmt | HL7-FHIR | Startup Ecosystem
2w
Dr Melissa Johnson, your talk on NSCLC & SCLC floored the audience. Spectacular talk !
"
"Melissa Johnson, MD
Director, Lung Cancer Research
Dr. Johnson joined Sarah Cannon in 2014 and serves as the director of lung cancer research. Her responsibilities include leading the lung cancer clinical trial portfolio across the Sarah Cannon network. Dr. Johnson continues to work in early phase drug development as well as lead the solid tumor immune effector cellular therapy program at Sarah Cannon. She also currently serves as the chair of the Cancer Committee at TriStar Centennial Medical Center in Nashville, Tenn."
https://sarahcannon.com/about/leadership/melissa-johnson
i'm very long here common and calls; just exploring 'every' nook and cranny
g/l
good point...
i also have posted that the Friday 'after the close' presentation is 'very' interesting
'but' i think the concern is why poster vs oral 'at' aacr...
g/l to us!
i see a few posters through various channels with concerns that we are only presenting 'posters' and not 'oral'; your thoughts?
again, i'm not a bio investor and don't know 1/100th of what you guys are referring to in this space BUT the gist of it seems to be it would be an
'oral' presentation if truly good?
thanks!
the problem with this is they mention strategic funding 'into 2023' .. seems small and shortsighted VS just saying strategic funding in general(?)
or maybe i'm reading too much into it........
'this'... yes please lol
i wasn't promoting it; never mentioned it as that's not my style .. no need to play child games
my question was genuine as i'm not much of a biotech investor and i knew that board would have the answer for me
and i do realize i'm playing with fire here as they 'do' have a history of not being shareholder friendly with their raises/dilution..etc.. BUT I love the risk/reward profile AND binary event
g/l!
while that may be true, I'm assuming their 'strategic plan' has more teeth to it than hoping warrant holders will exercise-
regarding 'strategic plans':
"
...
Fourth quarter 2021 financial results
...
Net loss: Net loss was $13.3 million...
....
Guidance
Genocea’s existing cash is sufficient to support our current operations into Q3 2022, however we have strategic plans to extend our operations into 2023.
...
"
So, assuming we're talking about these 'strategic plans' bringing us $25-$30million...
$25-$30million:
... could be (hoping!) a nice upfront payment on a partnership?
... would be ~25-30million share dilution if a raise at $1
... would be ~16.67-20million share dilution if a raise at $1.5
... would be ~12.5-15million share dilution if a raise at $2
won't be long now and we'll have some answers... g/l!
thanks for the reply and have a good day Bio
Are you inferring that the designation is a ruse to hide sub-optimal results? If so, it’s quite a different read than what I thought I heard Dew say(?)
you selling your .14's already ;) I have an aggressively sized holding in those at .1351 avg...... fingers crossed we get a partnership and not a low-ball placement
g/l!
thank you Dew!
Regarding the phrase "late-breaking clinical data" in reference to an AACR presentation, would that phrase technically be used for something positive only? I've seen the statement throughout the years but only infrequently invest in Biotechs so I'm not sure that I fully understand it's meaning-
Please forgive my ignorance; appreciate your help!
how interesting... presentation friday 'after' market close....
well accepting the bias (which is a known imo); yourself on jondoeuk seem very well-versed in the technology at hand-
so, bias aside.... 'if' the tech/solution works, are we talking about a 'possible' game-changer?
'if' i read the postings here correctly, i'm assuming you have a long position and that jondoeuk stated he'd wait to see the data before considering a position here(?)
thanks........g/l.............
MGR.V / MGLQF: appears to be the dreaded "doesn't appreciate under pm strength" but "goes down on pm weakness"
story is great; so we wait for interest-
g/l all